Commercial Collaborators
We are keen to work with industry partners of all shapes and sizes both within the UK and internationally. Whatever your challenge, our wide range of expertise and innovative thinking can bring a fresh approach to your product, process and service development. At present we are developing collaborative research grants within the SMART FIS initiative.
Get in touch via the Contact Us page or by emailing RBGO@swansea.ac.uk
AxisBio is a Northern Ireland-based pre-clinical contract research organisation with specialist capabilities in oncology. Axis Bio are working with RBGO as part of the CEAT project.
BiVictriX is a rapidly emerging biotechnology company applying a novel approach to develop safer, more effective cancer therapies. They specialise in the development of bi-specific antibody drug conjugates (ADC’s). This new class of therapeutic combines the selectivity of bi-specific antibodies with the potency of cutting-edge cytotoxic compounds.
BiVictriX have developed the Bi-Cygni® therapeutic platform, which is uniquely selective for particular cancer types, to enable higher dosing and more aggressive cancer eradication without causing harmful side-effects. BiVictriX are currently working with RBGO through the CEAT project; through this initiative, they intend to further develop their lead candidate and pipeline molecules.
Bruker enables scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker is collaborating with RBGO as part of the CEAT project.
Cytiva are a leading global medical technology and life sciences company that provide a broad portfolio of products, solutions and services used in the diagnosis, treatment and monitoring of patients and in the development and manufacture of biopharmaceuticals. GE Healcare is collaborating with RBGO on both the CEAT and CALIN projects.
GlaxoSmithKline have 3 global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. GSK is collaborating with RBGO as part of the CEAT project.
Ig-Innovations Ltd is a company with over 30 years experience in antibody production and immunoassay development. Ig Innovations is collaborating with RBGO as part of the RISE project.
Molecular Devices makes scientific breakthroughs possible for academic, pharmaceutical, government, and biotech customers. Dedicated to enabling life science labs of the future, where innovative technology and novel research converge, Molecular Devices empowers scientists to advance discovery, driving earlier diagnoses and safer therapeutics for patients.
ReNeuron is a leading, clinical-stage stem cell business. Their primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need. ReNeuron is collaborating with RBGO as part of the RISE project.
Porvair Sciences are global leaders in the manufacturing and development of porous plastics materials for life sciences and microplate technologies.
Specialising in the filtration and separation of biological samples, their revolutionary ChIP technology, Chromatrap pushes the boundaries of epigenetics research.
Porvair Sciences are collaborating with RBGO as part of the CEAT project.